© 2021 MJH Life Sciences and Gene Therapy Live. All rights reserved.
© 2021 MJH Life Sciences™ and Gene Therapy Live. All rights reserved.
June 22, 2021
Newly published data continues to demonstrate Zolgensma's efficacy in presymptomatic and symptomatic SMA Type 1.
June 03, 2021
Asklepios BioPharmaceuticals noted that it plans to initiate dosing for the LION-101 phase 1/2 clinical trial in the first half of 2022.
May 13, 2021
No adverse effects on weight, general activity, or survival in knockout mice and wild type littermates were observed throughout the study.
April 29, 2021
Apic Bio plans to initiate a phase 1/2 clinical trial in late 2021 or early 2022 as a multi-center, 3-part study to evaluate APB-102 in patients with SOD1-ALS mutations.